EGFR

44개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved44 programs
ADCCurated CoreFDADaiichi SankyoDXd (exatecan derivative, t…Approved

datopotamab deruxtecan (Datroway, DS-1062, Dato-DXd, datopotamab-deruxtecan-dlnk)

HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 50Status Approved
CGTStandard DatabasestaleAstraZenecaPhase 2

Epidermal growth factor receptor (EGFRv, Epidermal growth factor receptor, Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL)

Malignant Glioma; Glioblastoma · EGFR

#EGFR#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 61Status Active
AntibodyLimited DatastaleHuiKai LiPhase 2

Pucotenlimab (Pucotenlimab)

Biliary Tract Cancer (BTC); EGFR-positive Advanced Biliary Tract Carcinoma · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#Antibody#Phase2#monoclonal-antibody#BiliaryTractCancerBTC+2
Trials 42Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

CART-EGFR (CART-EGFR)

Advanced EGFR-positive Solid Tumors · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 9Status Active
CGTLimited DatastaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes)

Central Nervous System Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 6Status Recruiting
CGTLimited DatastaleCity of Hope Medical CenterPhase 2

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes)

Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 6Status Recruiting
CGTLimited DatastaleKite Pharma (a Gilead Company)Phase 1

CART-EGFR-IL13Ra2 Cells (CART-EGFR-IL13Ra2 Cells)

Glioblastoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 4Status Recruiting
CGTLimited DatastaleCity of Hope Medical CenterPhase 1

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes)

B Acute Lymphoblastic Leukemia; Recurrent Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 4Status Recruiting
CGTStandard DatabasestaleJuno Therapeutics, Inc., a Bris…Phase 2

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes)

CD19-Positive Neoplastic Cells Present; Recurrent Adult Acute Lymphoblastic Leukemia · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleJuno Therapeutics, Inc., a Bris…Phase 1

Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes)

Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent B-Cell Non-Hodgkin Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Discontinued
CGTLimited DatastaleGuangzhou Bio-gene Technology C…Phase 1

CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells (CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells)

Non Small Cell Lung Cancer · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Recruiting
AntibodyLimited DatastaleRoswell Park Cancer InstitutePhase 1

Nimotuzumab (Nimotuzumab)

EGFR Gene Mutation; Recurrent Non-Small Cell Lung Carcinoma · Advanced Cancer

#AdvancedCancer#Antibody#Phase1#monoclonal-antibody#EGFRGeneMutation+2
Trials 2Status Active
CGTLimited DatastaleCity of Hope Medical CenterPhase 1

autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells)

Adult Grade III Lymphomatoid Granulomatosis; Cutaneous B-cell Non-Hodgkin Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
ADCLimited DatastaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#antibody-drug-conjugate#Non-SmallCellLungCarcinoma+2
Trials 1Status Recruiting
CGTLimited DatastaleMustang Bio, Inc.Phase 1

Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes (Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes)

Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleBenaroya Research InstitutePhase 2

Panitumumab or Cetuximab (Anti-EGFR, Anti-EGFR (Panitumumab or Cetuximab))

Colorectal Cancer; Cholangiocarcinoma · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#ColorectalCancer+2
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

Metastatic Cancer; Metastatic Melanoma · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleAstraZenecaPhase 1

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014 (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014)

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleMustang Bio, Inc.Phase 1

Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes)

Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleXinqiao Hospital of ChongqingPhase 2

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

NSCLC Stage IV Without EGFR/ALK Mutation · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#NSCLCStageIVWithoutEGFR+2
Trials 1Status Recruiting

1 / 3 pages

← PreviousNext →